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Peripheral  LPS  induces  cholesterol  25-hydroxylase  expression  in  mouse  brain.
25-Hydroxycholesterol  upregulates  LXR  target  genes  in a  mouse  neuronal  cell  line.
25-Hydroxycholesterol  downregulates  neuronal  SREBP2-dependent  transcription.
25-Hydroxycholesterol  attenuates  neuronal  cholesterol  biosynthesis.
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Aberrant  oxysterol  biosynthesis  is  implicated  in  the  pathogenesis  of  neurodegenerative  diseases.  During
the  present  study  we  have  investigated  the  effects  of exogenously  added  25-hydroxycholesterol  (25-HC)
on  transcription  of  cholesterol  biosynthetic  genes,  sterol-regulatory  element  binding  protein  (SREBP)
processing  and  cholesterol  biosynthesis  in  the  murine  CATH.a  neuronal  cell  line.  A single  i.p. injection  of
lipopolysaccharide  resulted  in  robust  induction  of  cholesterol  25-hydroxylase  mRNA  and  protein  levels  in5-Hydroxycholesterol
holesterol 25-hydroxylase
xysterol
ndotoxin
euroinﬂammation
brains of  treated  mice.  In  vitro,  25-HC  upregulated  the  transcription  of  ATP-binding  cassette  transporter
A1  (ABCA1)  and  (to a  lesser  extent)  apolipoprotein  E (apoE)  in  CATH.a  neurons.  Cholesterol  biosynthetic
gene  expression  (squalene  synthase,  HMG-CoA  synthase,  HMG-CoA  reductase,  and  SREBP2)  was  down-
regulated  by  25-HC.  25-HC  also  signiﬁcantly  attenuated  proteolytic  processing  of  SREBP2.  Finally,  25-HC
downregulated  cholesterol  biosynthesis  in CATH.a  neurons.  Our  results  demonstrate  that  25-HC  is  a
 of  ne
.eurons potent  effector  oxysterol
. Introduction
The brain contains approx. 25% of total body cholesterol and the
ajority of cholesterol is produced by endogenous synthesis [4].
rain cholesterol biosynthesis is highest during development and
equires intact neuronal cholesterol biosynthetic pathways [10].
hen myelination is completed cholesterol biosynthesis decreases
nd glial cells synthesize and secrete apolipoprotein(apo)E-
ontaining lipoprotein particles, which are utilized by neurons as
holesterol source [31]. However, in the hippocampus neurons
xpress cholesterol biosynthetic genes suggesting that also mature
eurons retain the ability of cholesterol biosynthesis [40]. Part of
xcess neuronal cholesterol can be converted by acyl-coenzyme
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A:cholesterol acyltransferase 1 (ACAT1) to cholesteryl esters (CE),
which are stored intracellularly. Besides storage, neurons convert
excess cholesterol to 24(S)-hydroxycholesterol (24-HC; [4]) which
plays a dual role: First, 24-HC is a speciﬁc brain cholesterol metabo-
lite that is secreted via the blood–brain barrier into the circulation
where it is transported in association with lipoproteins and further
metabolized by the liver [4].  Second, 24-HC is a bioactive oxys-
terol that regulates the expression of enzymes centrally involved
in brain cholesterol homeostasis [41]. Apart from 24-HC the brain
is capable of synthesizing 25-HC and 27-HC via cholesterol 25-
hydroxylase (CH25H) and cholesterol 27-hydroxylase (CYP27A1)
[35]. Aberrant oxysterol synthesis is implicated in neurodegener-
ative diseases such as Alzheimer’s disease [25], multiple sclerosis
[21], or cerebrotendinous xanthomatosis [28].
Proinﬂammatory stimuli like lipopolysaccharide (LPS) lead to
Open access under CC BY-NC-ND licenseinduction of CH25H, the enzyme responsible for the formation of
25-HC [22]. Recent work identiﬁed both, CH25H and 25-HC as mod-
ulators of the immune response and inﬂammation [1,9,29]. Bauman
et al. [1] revealed a central role for 25-HC as regulator of the immune
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Fig. 1. CH25H mRNA and protein expression in brain of LPS-treated mice. Mice received a single i.p. injection of LPS (1.6 or 8.3 220 mg/kg) or PBS (vehicle, ‘v’). Animals were
killed  by cervical dislocation, brains were removed, RNA was isolated and TNF (A) and CH25H (B) mRNA expression was analyzed by qPCR at the indicated time points. cDNA
levels  were normalized to GAPDH as a reference gene and expressed relative to gene expression in vehicle controls. CH25H protein (C) was analyzed by Western blotting
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(densitometric evaluation of immunoreactive bands is shown). 25-HC concentrat
uantitated by GC–MS analysis. Expression analysis of selected gene products (E) 
esults  shown in (A), (B), (D), and (E) represent means ± SEM of three animals per t
ystem where this oxysterol is able to suppress Ig class switch
ecombination from IgM to IgA. CH25H in macrophages is rapidly
nduced upon treatment with LPS and low dose application of LPS
n healthy volunteers led to an increase in plasma 25-HC levels
ia Toll-like receptor (TLR)4-dependent pathways [9].  An alter-
ative pathway for suppression of TLR-mediated innate immune
esponse by 25-HC is provided by activation of liverXreceptor
LXR)-dependent pathways [6,18].  25-HC is a potent regulator of) in brains of vehicle- and LPS-treated mice (8.3 mg/kg body weight; 48 h) were
erformed by qPCR at the indicated time points post LPS (8.3 mg/kg body weight).
oint measured in triplicates. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. n.s. = not signiﬁcant.
LXR-mediated pathways, that impact on brain lipid homeosta-
sis [34], expression of the cholesterol efﬂux pumps ATP-binding
cassette transporter (ABC) A1 and ABCG1, and apoE expression
[5,20,38]. 25-HC is also able to stimulate LXR-independent oligo-
dendrocyte apoptosis and suppresses myelin gene expression in
peripheral nerves via LXR/Wnt/-catenin-mediated pathways [26].
25-HC can also act as a negative regulator of sterol regulatory
element binding protein (SREBP)-dependent pathways by binding
1 nce Letters 539 (2013) 16– 21
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Fig. 2. 25-HC induces ABCA1 and ApoE transcription in CATH.a cells. CATH.a cells
were incubated in the presence of increasing 25-HC concentrations. At the indicated
time points mRNA was  isolated and reverse transcribed. cDNA levels of ABCA1 (A)8 S. Waltl et al. / Neuroscie
o insulin-induced gene 1 and 2 anchor proteins (Insig1 and -2)
hereby inhibiting proteolytic activation of SREBPs [15].
Based on previous evidence the ﬁrst part of the study aimed at
nvestigating the consequences of a peripherally induced inﬂam-
ation on CH25H mRNA and protein expression in mouse brain
nder inﬂammatory conditions. In the second part we  sought to
larify effects of exogenously added 25-HC on transcriptional reg-
lation of cholesterol biosynthetic genes, SREBP processing, and
holesterol biosynthesis in the murine CATH.a neuronal cell line.
. Materials and methods
A detailed Materials and Methods section describing animal
xperiments [39], cell culture of CATH.a neurons [37], Western blot-
ing, GC–MS analysis, quantitative Real Time qPCR [30] (primers
n Supplemental Table I), measurement of SREBP2 processing and
holesterol biosynthesis [8],  and statistical procedures are given in
he Supplementary Information.
. Results and discussion
.1. Peripheral LPS induces CH25H mRNA and protein in murine
rain
In the ﬁrst set of experiments two different concentrations of LPS
ere used to induce inﬂammation. To conﬁrm a neuroinﬂamma-
ory response, brain TNF mRNA induction was analyzed by qPCR.
hese results revealed that TNF gene expression was elevated by
 maximum of 33- (1.6 mg/kg LPS; 3 h) and 64-fold (8.3 mg/kg LPS;
4 h) in comparison to control mice (PBS injected) (Fig. 1A). This is
n line with a comparable mouse model where brain TNF levels
emained elevated for several months [33]. Under our experimen-
al conditions a maximum induction of CH25H mRNA expression
f 7- (1.6 mg/kg LPS; 3 h) and 10-fold (8.3 mg/kg LPS; 24 h) was
bserved (Fig. 1B). Bauman et al. reported a 25-fold induction of
H25H mRNA in brains of mice exposed to the TLR agonist KDO
1].
Western blot analysis of CH25H in brain homogenates revealed
n apparent molecular mass of 36 kDa consistent with other
eports [16,22]. After 2, 4 and 8 days post LPS application an
nduction of CH25H protein (up to 3-fold higher as compared to
ontrols) was found (Fig. 1C). Compatibly, brain 25-HC concen-
rations increased signiﬁcantly from 4.3 (vehicle) to 11.2 (LPS;
 < 0.05) ng/mg wet tissue (Fig. 1D). These data are in line with
 report by Lütjohann et al. demonstrating that 25-HC concen-
rations are below 3% of 24-HC concentrations in human brain
24]. The expression levels of selected genes involved in brain
holesterol homeostasis were also altered in response to LPS
Fig. 1E). LPS treatment induced a (statistically not signiﬁcant)
ecrease of 3-hydroxy-3-methylglutaryl-CoA synthase (HMGCS1;
esponsible for the formation of HMG-CoA from acetyl-CoA and
cetoacetyl-CoA) and HMG-CoA reductase (HMGCR; catalyzing the
ate-limiting step of cholesterol biosynthesis from HMG-CoA to
evalonate; [14]). In contrast, ABCA1 was signiﬁcantly upregu-
ated at all time points investigated, while apoE induction reached
tatistical signiﬁcance only at 3 h post LPS (Fig. 1E).
.2. 25-HC as transcriptional regulator of cholesterol homeostasis
n murine CATH.a neurons
In vitro, 25-HC upregulated mRNA levels of ABCA1 (maximum of
.6-fold at 12 h; Fig. 2A) and to a lesser extent also of apoE (1.7-fold)
t high 25-HC concentrations and later (12 h) time points (Fig. 2B).
Next transcriptional changes in genes involved in CATH.a
holesterol biosynthesis were studied. 25-HC induced aand ApoE (B) were normalized to -actin as a reference gene and expressed relative
to  gene expression in vehicle (‘v’) controls (ethanol, 0.05%). Results represent means
of  triplicates ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
pronounced downregulation (1.8- to 2.6-fold) of farnesyl-
diphosphate farnesyltransferase (FDFT1; the enzyme responsible
for squalene synthesis from farnesyl diphosphate) transcription
(Fig. 3A). Treatment of cells with 25-HC led to a robust down-
regulation of HMGCS1 in neurons in a concentration-dependent
manner (Fig. 3B). 25-HC signiﬁcantly decreased expression of
HMGCR by a maximum of 60% at 12 h (Fig. 3C). Finally, 25-HC
induced a pronounced decrease in transcription of SREBP2, where
reduction was concentration-dependent reaching levels of approx.
50% as compared to baseline levels (Fig. 3D). Immunoblot analyses
(Fig. 4) revealed that proteolytic processing of SREBP2 protein is
signiﬁcantly attenuated at 100 nM 25-HC with almost no mature
SREBP2 detectable at 1 M 25-HC. In healthy human volunteers,
plasma 25-HC levels are approx. 5 nM [12] but can reach con-
centrations of about 500 nM in patients that carry mutations in
the gene coding for the oxysterol 7 alpha hydroxylase (CYP7B1)
[36]. These are 25-HC concentrations that potently affect SREBP
processing in vitro (Fig. 4).3.3. 25-HC impairs cholesterol biosynthesis
CATH.a cells were pre-incubated with 25-HC and [14C]acetate
(2 Ci/well) as cholesterol precursor. At the indicated time points
S. Waltl et al. / Neuroscience Letters 539 (2013) 16– 21 19
Fig. 3. 25-HC impairs cholesterol biosynthetic gene transcription. CATH.a cells were incubated in the presence of increasing 25-HC concentrations. At the indicated time
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toints mRNA was  isolated and reverse transcribed. cDNA levels of FDFT1 (A), HMG
xpressed relative to gene expression in vehicle (‘v’) controls (ethanol, 0.05%). Resu
ipids were extracted, separated by TLC and bands co-migrating
ith free cholesterol and cholesteryl ester (CE) standards were
ut out and subjected to scintillation counting. These experiments
emonstrated that at 2.5 and 5 M 25-HC cholesterol biosynthesis
s signiﬁcantly inhibited by 30 and 55%, respectively (Fig. 5A). The
adioactivity recovered from the CE fraction was  approx. 8% of total
adioactivity under control conditions, indicating low neuronal CE
ynthesis (Fig. 5B). 25-HC treatment signiﬁcantly increased the
ercentage radioactivity in the CE fraction to 11 and 21% of total
FC + CE) radioactivity (2.5 and 5 M 25-HC) indicating ACAT acti-
ation in response to 25-HC. This is in line with previous reports
here 25-HC activates ACAT-mediated cholesterol esteriﬁcation
ig. 4. 25-HC inhibits SREBP2 activation. CATH.a cells were serum-starved (5% LPDS)
or  4 h in the presence of 50 M mevalonate, 10 M compactin and 25-HC at the indi-
ated concentrations. Total cell protein was  isolated and mature SREBP2 (mSREBP2)
as  detected by Western blotting (A). -actin was used as loading control. Graphical
epresentation of relative optical densities of immunoreactive SREBP2 normalized
o  those of -actin is shown in (B).), HMGCR (C), and SREBP2 (D) were normalized to -actin as a reference gene and
resent means of triplicates ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
in CHO cells [11] and enterocytes [13]. This might be of impor-
tance for neuronal function since ACAT antagonism alters amyloid
 processing in vitro [32] and ameliorates amyloid pathology in a
mouse model of Alzheimer’s disease [17].
Radioactivity recovered from the cholesterol fraction in the
medium under control conditions was relatively high (40% of cell-
associated activity) indicating efﬁcient cholesterol efﬂux by CATH.a
cells. In response to 2.5 and 5 M 25-HC, cholesterol radioactivity
in the medium decreased to approx. 50 and 30% of controls (Fig. 5C),
comparable to what was  observed for the cellular cholesterol pool.
In contrast, the contribution of medium CE radioactivity is rather
low (approx. 6% of total CE radioactivity; Fig. 5D).
Side chain-oxidized cholesterol metabolites have the unique
ability to limit cellular cholesterol levels in vitro [15]. A major ques-
tion arising is the ability of oxysterols to interfere with cholesterol
homeostasis in vivo. This is due to the fact that a 100- to 500-fold
excess of cholesterol will compete for oxysterol binding to LXR
[3]. Currently murine knockout models are available for the three
major cholesterol hydroxylases contributing to oxysterol synthesis
in the brain. Deletion of CYP46A1 (CH24H) leads to signiﬁcantly
reduced CNS cholesterol synthesis and excretion. This might be
a reﬂection of cholesterol turnover in a metabolically active sub-
set of neurons where the majority of CH24H is expressed [23]. In
−/−addition CH24H mice exhibit severely impaired learning abili-
ties [19]. Deletion of CYP27A1 (CH27H) in mice leads to increased
cholestanol levels in the brain [2],  a condition reminiscent of what
is observed in patients with cerebrotendinous xanthomatosis who
20 S. Waltl et al. / Neuroscience Letters 539 (2013) 16– 21
Fig. 5. 25-HC impairs cholesterol biosynthesis. Cells received medium containing the indicated concentrations of 25-HC and [14C]acetate (2 Ci/well). After 6 h cellular
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(nd  medium lipids were extracted, separated by TLC and the bands co-migrating
adioactivity was  counted on a -counter. ‘v’ = vehicle control (ethanol). Results sh
ere  calculated with 1-way ANOVA followed by a Bonferroni post-test. *p≤0.05, **
arry mutations in the CYP27A1 gene [28]. In the CYP27A1−/−
ice increased lathosterol concentrations in the cerebrum were
uggested to be indicative for increased cholesterol biosynthe-
is [2].  A recent report identiﬁed CYP27A1 deletion in the mouse
s a causative factor for defective retinal cholesterol homeosta-
is [27]. In addition, abnormal neovascularization in the retina of
YP27A1−/− mice reproduced some features observed in patients
ith age-related macular degeneration [27]. CH25H knockout leads
o decreased levels of 25-HC in the lung and serum of knockout
ice and severely impacts on serum IgA levels [1].  Finally a triple
nockout of CYP46A1, CYP27A1, and CH25H failed to induce tran-
cription of LXR target genes in response to a high cholesterol
iet [7].  These reports strongly suggest that oxysterols are in vivo
egulators of cholesterol homeostasis in different organs includ-
ng the brain. Data of the present study indicate that CH25H is
pregulated under neuroinﬂammatory conditions in vivo and that
5-HC is a potent regulator of neuronal cholesterol homeostasis
n vitro.
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